Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Paracoccidioidomycosis

  • Author: Duane R Hospenthal, MD, PhD, FACP, FIDSA, FASTMH; Chief Editor: Mark R Wallace, MD, FACP, FIDSA  more...
 
Updated: Mar 23, 2015
 

Practice Essentials

Paracoccidioidomycosis is a fungal infection endemic to South and Central America, most notably Brazil, Argentina, Colombia, and Venezuela (see the image below). It is caused by the thermally dimorphic fungi Paracoccidioides brasiliensis and Paracoccidioides lutzii.[1] Although the infection is usually subclinical, the fungus can also cause chronic and severe disease.

Approximate distribution of paracoccidioidomycosis Approximate distribution of paracoccidioidomycosis in North, Central, and South America, based on case reports.

The 2 general clinical categories of paracoccidioidomycosis are (1) an acute/subacute form (juvenile paracoccidioidomycosis) and (2) a chronic form (adult paracoccidioidomycosis).

Signs and symptoms

Juvenile form

  • Lymphadenopathy and hepatosplenomegaly
  • Systemic symptoms - Include fever, weight loss, and malaise; present in most patients.
  • Symptoms related to lymph node enlargement, suppuration, and sinus tract formation
  • Multiple skin lesions
  • Mucous membrane and respiratory symptoms - These are unusual

Adult form

  • Primary lung infection - Cough (productive or nonproductive), dyspnea, malaise, fever, and weight loss are common symptoms
  • Chronic pulmonary sequelae - Develop in one third of patients; can include pulmonary fibrosis, bullae, and emphysematous changes that can contribute to pulmonary hypertension and cor pulmonale in 5% of cases.
  • Mucous membrane involvement - Occurs in 50% of patients with acute pulmonary infection; includes laryngeal and pharyngeal lesions
  • Oral lesions - May be associated with nasal and pharyngeal ulcers (Aguiar-Pupo stomatitis) and with mandibular or cervical lymph node enlargement
  • Cutaneous lesions - Caused by hematologic dissemination from the lungs; occur in 25% of patients; crusted papules, ulcers, nodules, plaques, and verrucous lesions are typical
  • Lymphadenopathy - Most common in the cervical region

Diagnosis

The diagnosis of paracoccidioidomycosis is most commonly made by visualization of the yeast cells in tissue, wet preparations (eg, sputum), or superficial scrapings (eg, skin lesions). Serological tests are available in areas of highest endemicity. In patients with active paracoccidioidomycosis, chest radiography reveals interstitial infiltrates (in 64% of cases) or mixed lesions with linear and nodular infiltrates.

Management

Systemic antifungal medications are the mainstay of medical management in paracoccidioidomycosis. Supportive measures and hospitalization may be warranted for patients with severe disease. If present, anemia and nutritional deficiencies should be treated. Antifungals effective against paracoccidioidomycosis include the following:

  • Triazoles - Itraconazole, voriconazole, and posaconazole; itraconazole is considered the drug of choice for paracoccidioidomycosis
  • Imidazoles - Ketoconazole
  • Sulfonamides - Sulfadiazine, trimethoprim/sulfamethoxazole
  • Amphotericin B - Reserved for severe cases of paracoccidioidomycosis that are refractory to other forms of therapy

Surgery

Occasionally, specific surgical treatments are warranted for life- or organ-threatening disease, such as neurosurgical procedures to relieve granuloma-induced spinal cord compression or hydrocephalus. Reconstructive surgery is sometimes needed to alleviate fibrotic sequelae.

Next

Background

Paracoccidioidomycosis, formerly known as South American blastomycosis and Lutz-Splendore-Almeida disease, is a fungal infection endemic to South and Central America, most notably Brazil, Argentina, Colombia, and Venezuela (see the image below). (See Epidemiology.)

Approximate distribution of paracoccidioidomycosis Approximate distribution of paracoccidioidomycosis in North, Central, and South America, based on case reports.

Paracoccidioidomycosis is caused by the thermally dimorphic fungi Paracoccidioides brasiliensis and P lutzii.[1] Infection is usually subclinical. The fungus can proliferate, however, causing severe disease. (See Pathophysiology, Etiology, Prognosis, and Workup.)[2]

Paracoccidioidomycosis most commonly manifests as a chronic, progressive, systemic mycosis in men from the forested tropical and subtropical regions of Latin America. Pulmonary infection is the most common manifestation. Following dissemination, however, paracoccidioidomycosis frequently involves the mucous membranes (primarily of the oral cavity),[3] skin, and lymph nodes. (See Pathophysiology and Clinical Presentation.)

The 2 general clinical categories of paracoccidioidomycosis are (1) an acute/subacute form (juvenile paracoccidioidomycosis) and (2) a chronic form (adult paracoccidioidomycosis).

The following are noted for juvenile paracoccidioidomycosis:

  • Accounts for 5-10% of cases
  • Rapid progression after recent exposure
  • More common in children and adolescents
  • Tends to involve reticuloendothelial system with more severe disease

The following are noted for adult paracoccidioidomycosis:

  • Accounts for more than 90% of cases
  • Reactivation months to years after exposure
  • More common in adult males
  • Can be unifocal, affecting only 1 organ (lungs most commonly), or multifocal, affecting multiple organs
  • Lungs, mucous membranes, skin, and lymph nodes are most frequently involved

Paracoccidioides infection has been reported in the 9-banded armadillo, dogs, and other animals.[4, 5, 6] Animal-to-human transmission has not been reported. (See Pathophysiology and Etiology.)

Previous
Next

Pathophysiology

Paracoccidioidomycosis is caused by Paracoccidioides brasiliensis and P lutzii, thermally dimorphic fungi that grow as mycelium in nature and in culture at 18-23°C, and as yeast in human tissue and in culture at 37C°.[1] The lungs are the primary site of infection, likely secondary to inhalation of conidia or mycelial fragments.

After inhalation of the conidia, the fungus transforms into yeast cells within the alveolar macrophages. This transformation induces a nonspecific inflammatory response, which generally limits the disease at this point. Therefore, in most patients who are immunocompetent, the infection is asymptomatic and resolves without medical intervention. Less commonly, after an incubation period of weeks to decades, the fungus can disseminate through the venous and lymphatic systems, causing granulomatous disease in multiple tissues. (See the image below.)[7]

Granulomatous lesion involving the nose in patient Granulomatous lesion involving the nose in patient with paracoccidioidomycosis; note the resemblance to cutaneous leishmaniasis.

Direct inoculation of the skin or oral mucous membranes is not believed to be common but may result from the use of twigs to clean teeth, which is practiced in rural Brazil. The intestinal mucosa may serve as a site of direct inoculation if Paracoccidioides is ingested.

Cutaneous lesions can result from direct extension, hematogenous dissemination, or lymphatic dissemination.

Naturally acquired Paracoccidioides infection in animals has been reported only in armadillos. However, bats and saguis may serve as reservoirs. Animal-to-human and human-to-human transmissions do not appear to occur.

Previous
Next

Etiology

Risk factors for paracoccidioidomycosis include the following[8] :

  • Agricultural work (especially coffee growers in Brazil) - The fungi are believed to reside in soil
  • Malnutrition
  • Smoking
  • Alcoholism
  • Immunodeficiency - Eg, from HIV/AIDS

Paniago et al found that the incidence of paracoccidioidomycosis in patients with HIV/AIDS was higher than that of the general population (1.5% vs 0.02%, respectively).[9] Patients with AIDS are more likely to develop hematogenous dissemination and multiple organ involvement (juvenile-type disease).[10] Alcohol consumption and possibly tobacco smoking are also associated with disseminated disease.[11]

Otherwise-healthy patients who develop disseminated disease appear unable to mount a sufficient cellular immune response to the organism.

Previous
Next

Epidemiology

United States

Paracoccidioides is not endemic to the United States, but paracoccidioidomycosis has been reported in North America and elsewhere in patients who had previously visited or resided in endemic areas.[12] These cases are believed to have resulted from reactivation of latent infection

Worldwide

Paracoccidioidomycosis is restricted geographically to South and Central America, from Mexico to Argentina, with the exception of Chile, Surinam, Guiana, Nicaragua, Belize, and most of the Caribbean islands.[8]

Within endemic regions, paracoccidioidomycosis is restricted to coffee- or tobacco-growing areas, areas with acidic soils, and areas with temperatures between 12°C and 30°C, altitudes between 150 and 2000 m, and annual rainfall between 100 and 400 cm.

Of the 90 million people living in endemic areas, approximately 10 million are infected with Paracoccidioides, although exact figures are difficult to obtain.[13] Positive paracoccidioidin skin test results have been reported in 6-50% of people living in endemic areas, indicating prior exposure.

The highest incidence of the disease is in Brazil (approximately 80% of cases), followed by Colombia, Venezuela, Ecuador, and Argentina. Antibodies to P brasiliensis have been detected in 27% of blood donors in Brazil. (See the image below.)[14, 15, 16, 17]

Approximate distribution of paracoccidioidomycosis Approximate distribution of paracoccidioidomycosis in North, Central, and South America, based on case reports.

Sex-related demographics

The acute/subacute juvenile form of paracoccidioidomycosis affects both sexes equally, but the chronic, adult form of the disease affects men more frequently than women, with a reported ratio ranging from 6:1 to 15:1.

Paracoccidioides has receptors that bind estrogen. Binding of estrogen prevents the transformation of the mycelium into the yeast phase, which is necessary for tissue invasion.[18] This inhibition has been hypothesized to explain the sex differences in the occurrence of paracoccidioidomycosis, despite the fact that equal numbers of men and women have positive paracoccidioidin skin test results and that equal numbers of prepubertal boys and girls have the acute/subacute juvenile type.

Age-related demographics

The acute/subacute form of paracoccidioidomycosis is more common in children and adolescents. The chronic form of the disease is more common in adult males aged 30-50 years.

Previous
Next

Prognosis

With appropriate antifungal therapy, most patients with paracoccidioidomycosis survive. Relapses are common, however, and patients must be evaluated regularly.

Complications of the disease include the following:

  • General - Malnourishment and anemia
  • Pulmonary - Hemoptysis, pulmonary fibrosis, and chronic cor pulmonale
  • Endocrine - Addison syndrome
  • Wound infection - Superinfection with bacteria or other fungal pathogens is always a concern in paracoccidioidomycosis because patients often have open wounds and an immune system that is already under stress. Superinfection can significantly complicate recovery or even lead to sepsis and death
  • Fibrosis - Complications in paracoccidioidomycosis generally result from fibrotic scarring that occurs during healing. Patients can have chronic, residual lung, oral, nasal, pharyngeal, and laryngeal problems after the lungs or mucous membranes heal. The destruction of mucous membranes can lead to perforation of the palate or nasal septum, while the destruction of the adrenal glands can cause Addison disease. Even with adequate treatment of paracoccidioidomycosis, the severe fibrosis that accompanies healing often results in long-term sequelae, such as disfiguring facial scarring, chronic dyspnea and cor pulmonale (from severe pulmonary fibrosis), and buccal atresia, dysphonia, and laryngeal and tracheal stenosis (from mucous membrane scarring)

Mortality

The mortality rate likely depends on the severity of the infection, organ systems involved, the age and sex of the patient, other comorbidities, and immune status (eg, the mortality rate is higher for patients with HIV).

A study in Brazil, where paracoccidioidomycosis has been reported as the eighth leading cause of death,[3] showed a mean mortality rate of 1.45 deaths per 1 million inhabitants and a nationwide, area-associated mortality rate of 3.73 deaths per 10,000 km2. Males tended to have a higher mortality rate than females.[19]

The mortality rate for children with acute paracoccidioidomycosis has been reported to be 7-10%.[20]

Previous
 
 
Contributor Information and Disclosures
Author

Duane R Hospenthal, MD, PhD, FACP, FIDSA, FASTMH Adjunct Professor of Medicine, Department of Medicine, University of Texas Health Science Center at San Antonio

Duane R Hospenthal, MD, PhD, FACP, FIDSA, FASTMH is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, International Society for Infectious Diseases, International Society of Travel Medicine, Medical Mycological Society of the Americas, Armed Forces Infectious Diseases Society, International Society for Human and Animal Mycology, American College of Physicians, American Society for Microbiology, Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Coauthor(s)

Kendall M Egan, MD, FAAD Dermatologist, Veteran's Affairs Medical Center; Dermatologist, Spruce Health, Dermatologist, DermOne

Kendall M Egan, MD, FAAD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists

Disclosure: Nothing to disclose.

Chief Editor

Mark R Wallace, MD, FACP, FIDSA Clinical Professor of Medicine, Florida State University College of Medicine; Clinical Professor of Medicine, University of Central Florida College of Medicine

Mark R Wallace, MD, FACP, FIDSA is a member of the following medical societies: American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, International AIDS Society, Florida Infectious Diseases Society

Disclosure: Nothing to disclose.

Acknowledgements

Asgar A Boxwalla, MD Staff Physician, Department of Internal Medicine, Division of Infectious Diseases, St John Detroit Riverview Hospital

Disclosure: Nothing to disclose.

David F Butler, MD Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Pranatharthi Haran Chandrasekar, MBBS, MD Professor, Department of Internal Medicine, Director of Infectious Disease Fellowship, Harper Hospital, Wayne State University School of Medicine

Pranatharthi Haran Chandrasekar, MBBS, MD is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Julie E Dixon, MD, FAAD Private Practice, Ironwood Dermatology, Tucson, Arizona

Julie E Dixon, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and American Medical Association

Disclosure: Nothing to disclose.

Dirk M Elston, MD Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Franklin Flowers, MD Chief, Division of Dermatology, Professor, Department of Medicine and Otolaryngology, Affiliate Associate Professor of Pediatrics and Pathology, University of Florida College of Medicine

Franklin Flowers, MD, is a member of the following medical societies: American College of Mohs Micrographic Surgery and Cutaneous Oncology

Disclosure: Nothing to disclose.

Ronald A Greenfield, MD Professor, Department of Internal Medicine, University of Oklahoma College of Medicine

Ronald A Greenfield, MD is a member of the following medical societies: American College of Physicians, American Federation for Medical Research, American Society for Microbiology, Central Society for Clinical Research, Infectious Diseases Society of America, Medical Mycology Society of the Americas, Phi Beta Kappa, Southern Society for Clinical Investigation, and Southwestern Association of Clinical Microbiology

Disclosure: Pfizer Honoraria Speaking and teaching; Gilead Honoraria Speaking and teaching; Ortho McNeil Honoraria Speaking and teaching; Abbott Honoraria Speaking and teaching; Astellas Honoraria Speaking and teaching; Cubist Honoraria Speaking and teaching; Forest Pharmaceuticals Speaking and teaching

Norman Levine, MD Private Practice, Tucson, AZ

Norman Levine is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Jeffrey J Miller, MD Associate Professor of Dermatology, Pennsylvania State University College of Medicine; Staff Dermatologist, Pennsylvania State Milton S Hershey Medical Center

Jeffrey J Miller, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Association of Professors of Dermatology, North American Hair Research Society, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Christina M Schofield, MD Instructor of Medicine, Uniformed Services University of the Health Sciences; Consulting Staff, Department of Infectious Disease, Wilford Hall Medical Center, Lackland Air Force Base

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Acknowledgments

The views expressed in this manuscript are those of the authors and do not reflect the official policy of the Department of the Navy, Department of the Army, Department of Defense, or the U.S. Government.

References
  1. Marques-da-Silva SH, Rodrigues AM, de Hoog GS, Silveira-Gomes F, Camargo ZP. Occurrence of Paracoccidioides lutzii in the Amazon region: description of two cases. Am J Trop Med Hyg. 2012 Oct. 87(4):710-4. [Medline]. [Full Text].

  2. Lupi O, Tyring SK, McGinnis MR. Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol. 2005 Dec. 53(6):931-51, quiz 952-4. [Medline].

  3. Brazão-Silva MT, Andrade MF, Franco T, Ribeiro RI, Silva Wdos S, Faria G, et al. Paracoccidioidomycosis: a series of 66 patients with oral lesions from an endemic area. Mycoses. 2011 Jul. 54(4):e189-95. [Medline].

  4. Bagagli E, Sano A, Coelho KI, Alquati S, Miyaji M, de Camargo ZP, et al. Isolation of Paracoccidioides brasiliensis from armadillos (Dasypus noveminctus) captured in an endemic area of paracoccidioidomycosis. Am J Trop Med Hyg. 1998 Apr. 58(4):505-12. [Medline].

  5. de Farias MR, Condas LA, Ribeiro MG, Bosco Sde M, Muro MD, Werner J, et al. Paracoccidioidomycosis in a dog: case report of generalized lymphadenomegaly. Mycopathologia. 2011 Aug. 172(2):147-52. [Medline].

  6. Trejo-Chávez A, Ramírez-Romero R, Ancer-Rodríguez J, Nevárez-Garza AM, Rodríguez-Tovar LE. Disseminated paracoccidioidomycosis in a Southern two-toed sloth (Choloepus didactylus). J Comp Pathol. 2011 Feb-Apr. 144(2-3):231-4. [Medline].

  7. Benard G, Kavakama J, Mendes-Giannini MJ, Kono A, Duarte AJ, Shikanai-Yasuda MA. Contribution to the natural history of paracoccidioidomycosis: identification of the primary pulmonary infection in the severe acute form of the disease--a case report. Clin Infect Dis. 2005 Jan 1. 40(1):e1-4. [Medline].

  8. Bellissimo-Rodrigues F, Bollela VR, Da Fonseca BA, Martinez R. Endemic paracoccidioidomycosis: relationship between clinical presentation and patients' demographic features. Med Mycol. 2013 Apr. 51(3):313-8. [Medline].

  9. Paniago AM, de Freitas AC, Aguiar ES, Aguiar JI, da Cunha RV, Castro AR, et al. Paracoccidioidomycosis in patients with human immunodeficiency virus: review of 12 cases observed in an endemic region in Brazil. J Infect. 2005 Oct. 51(3):248-52. [Medline].

  10. Corti M, Villafañe MF, Negroni R, Palmieri O. Disseminated paracoccidioidomycosis with peripleuritis in an AIDS patient. Rev Inst Med Trop Sao Paulo. 2004 Jan-Feb. 46(1):47-50. [Medline].

  11. Azenha MR, Caliento R, Brentegani LG, de Lacerda SA. A retrospective study of oral manifestations in patients with paracoccidioidomycosis. Braz Dent J. 2012. 23(6):753-7. [Medline].

  12. Mayr A, Kirchmair M, Rainer J, Rossi R, Kreczy A, Tintelnot K, et al. Chronic paracoccidioidomycosis in a female patient in Austria. Eur J Clin Microbiol Infect Dis. 2004 Dec. 23(12):916-9. [Medline].

  13. Blotta MH, Mamoni RL, Oliveira SJ, Nouér SA, Papaiordanou PM, Goveia A, et al. Endemic regions of paracoccidioidomycosis in Brazil: a clinical and epidemiologic study of 584 cases in the southeast region. Am J Trop Med Hyg. 1999 Sep. 61(3):390-4. [Medline].

  14. Maluf ML, Pereira SR, Takahachi G, Svidzinski TI. [Prevalence of paracoccidioidomycosis infection determined by sorologic test in donors' blood in the Northwest of Paraná, Brazil]. Rev Soc Bras Med Trop. 2003 Jan-Feb. 36(1):11-6. [Medline].

  15. Cabral-Marques O, Schimke LF, Pereira PV, Falcai A, de Oliveira JB, Hackett MJ, et al. Expanding the clinical and genetic spectrum of human CD40L deficiency: the occurrence of paracoccidioidomycosis and other unusual infections in Brazilian patients. J Clin Immunol. 2012 Apr. 32(2):212-20. [Medline].

  16. Nogueira LM, Santos M, Ferreira LC, Talhari C, Rodrigues RR, Talhari S. AIDS-associated paracoccidioidomycosis in a patient with a CD4+ T-cell count of 4 cells/mm³. An Bras Dermatol. 2011 Jul-Aug. 86(4 Suppl 1):S129-32. [Medline].

  17. Desjardins CA, Champion MD, Holder JW, Muszewska A, Goldberg J, Bailão AM, et al. Comparative genomic analysis of human fungal pathogens causing paracoccidioidomycosis. PLoS Genet. 2011 Oct. 7(10):e1002345. [Medline]. [Full Text].

  18. Shankar J, Restrepo A, Clemons KV, Stevens DA. Hormones and the resistance of women to paracoccidioidomycosis. Clin Microbiol Rev. 2011 Apr. 24(2):296-313. [Medline]. [Full Text].

  19. Coutinho ZF, Silva Dd, Lazera M, Petri V, Oliveira RM, Sabroza PC, et al. Paracoccidioidomycosis mortality in Brazil (1980-1995). Cad Saude Publica. 2002 Sep-Oct. 18(5):1441-54. [Medline].

  20. Pereira RM, Tresoldi AT, da Silva MT, Bucaretchi F. Fatal disseminated paracoccidioidomycosis in a two-year-old child. Rev Inst Med Trop Sao Paulo. 2004 Jan-Feb. 46(1):37-9. [Medline].

  21. de Almeida SM, Queiroz-Telles F, Teive HA, Ribeiro CE, Werneck LC. Central nervous system paracoccidioidomycosis: clinical features and laboratorial findings. J Infect. 2004 Feb. 48(2):193-8. [Medline].

  22. Moreto TC, Marques ME, de Oliveira ML, Moris DV, de Carvalho LR, Mendes RP. Accuracy of routine diagnostic tests used in paracoccidioidomycosis patients at a university hospital. Trans R Soc Trop Med Hyg. 2011 Aug. 105(8):473-8. [Medline].

  23. Hahn RC, Rodrigues AM, Fontes CJ, Nery AF, Tadano T, Queiroz Lde P Jr. Fatal fungemia due to Paracoccidioides lutzii. Am J Trop Med Hyg. 2014 Aug. 91(2):394-8. [Medline].

  24. Kalmar EM, Alencar FE, Alves FP, et al. Paracoccidioidomycosis: an epidemiologic survey in a pediatric population from the Brazilian Amazon using skin tests. Am J Trop Med Hyg. 2004 Jul. 71(1):82-6. [Medline].

  25. Freitas RM, Prado R, Prado FL, Paula IB, Figueiredo MT, Ferreira CS, et al. Pulmonary paracoccidioidomycosis: radiology and clinical-epidemiological evaluation. Rev Soc Bras Med Trop. 2010 Nov-Dec. 43(6):651-6. [Medline].

  26. Reis F, Collier PP, Souza TF, Lopes GP, Bronzatto E, Silva Junior NA, et al. Neuroparacoccidioidomycosis (NPCM): magnetic resonance imaging (MRI) findings. Mycopathologia. 2013 Feb. 175(1-2):181-6. [Medline].

  27. Queiroz-Telles F, Goldani LZ, Schlamm HT, Goodrich JM, Espinel-Ingroff A, Shikanai-Yasuda MA. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis. 2007 Dec 1. 45(11):1462-9. [Medline].

  28. Borges SR, Silva GM, Chambela Mda C, Oliveira Rde V, Costa RL, Wanke B, et al. Itraconazole vs. trimethoprim-sulfamethoxazole: A comparative cohort study of 200 patients with paracoccidioidomycosis. Med Mycol. 2014 Apr. 52(3):303-10. [Medline].

  29. Travassos LR, Taborda CP, Colombo AL. Treatment options for paracoccidioidomycosis and new strategies investigated. Expert Rev Anti Infect Ther. 2008 Apr. 6(2):251-62. [Medline].

  30. Ollague JM, de Zurita AM, Calero G. Paracoccidioidomycosis (South American blastomycosis) successfully treated with terbinafine: first case report. Br J Dermatol. 2000 Jul. 143(1):188-91. [Medline].

 
Previous
Next
 
Approximate distribution of paracoccidioidomycosis in North, Central, and South America, based on case reports.
Granulomatous lesion involving the nose in patient with paracoccidioidomycosis; note the resemblance to cutaneous leishmaniasis.
Potassium hydroxide (KOH) preparation from pus; note the multiple budding and variation in cell size with Paracoccidioides.
Crusted plaques over the central part of the face in a man with paracoccidioidomycosis. Courtesy of Rolando Vasquez, MD, Professor of Dermatology, Guatemala.
Ulcerated nodule on the tongue in a man with paracoccidioidomycosis. Courtesy of Heidi Logemann, Professor of Mycology, Universidad de San Carlos, Guatemala.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.